title: Telithromycin: the first of the ketolides.
abstract: OBJECTIVE
  To review the chemistry, spectrum of activity, pharmacology, clinical efficacy, and safety of telithromycin.
  
  
  METHODS
  A MEDLINE search from 1966 to December 2000 was performed via OVID and PubMed using the following search terms: HMR 3647, HMR3647, Ketek, RU 66647, and telithromycin. An extensive review of retrieved literature, abstracts from international scientific conferences, and minutes from regulatory authority meetings was also performed.
  
  
  METHODS
  Medicinal chemistry, in vitro, animal, and human trials were reviewed for information on the antimicrobial activity, clinical efficacy, pharmacology, and safety of telithromycin.
  
  
  RESULTS
  Several chemical modifications to the macrolide structure have led to the development of telithromycin, the first ketolide antimicrobial that demonstrates improved activity against penicillin- and macrolide/azalide-resistant Streptococcus pneumoniae due to its unique binding to the ribosomal target site. Although telithromycin may be useful in the treatment of community-acquired respiratory tract infections due to its activity against common typical and atypical pathogens, questions concerning its reliable activity against Haemophilus influenzae need to be addressed. Telithromycin's pharmacokinetics permit once-daily dosing for abbreviated periods and good distribution into lung tissue and phagocytic cells. Clinical and bacteriologic cure rates have been similar to those of comparator agents in human efficacy trials; however, the incidence of adverse gastrointestinal events were generally higher with telithromycin patients. Like other macrolides and many newer fluoroquinolones, telithromycin's ability to prolong the QTc interval is a potential safety issue, especially in elderly patients with predisposing conditions or those who are concurrently receiving drugs that are substrates for CYP2D6 and 3A4. Liver function test elevations demonstrated during clinical trials, although not overtly severe, may warrant monitoring in some patients taking multiple hepatically metabolized/cleared agents.
  
  
  CONCLUSIONS
  Telithromycin offers potential advantages over traditional macrolides/azalides for community-acquired respiratory tract infections caused by macrolide-resistant pathogens. Further studies are needed to elucidate its clinical efficacy against H. influenzae, potential drug interactions, and safety in various subpopulations.
authors.affiliation: Clinical Pharmacology Research Center, Bassett Healthcare, Cooperstown, NY 13326-1394, USA.
authors.forename: Christopher S
authors.initials: CS
authors.lastname: Shain
authors.forename: Guy W
authors.initials: GW
authors.lastname: Amsden
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use; D019540:Area Under Curve; D001682:Biological Availability; D004347:Drug Interactions; D006801:Humans; D007408:Intestinal Absorption; D048628:Ketolides; D018942:Macrolides; D008297:Male; D008826:Microbial Sensitivity Tests; D012141:Respiratory Tract Infections / Q000188:drug therapy*
chemical_list: D000900:Anti-Bacterial Agents; D048628:Ketolides; D018942:Macrolides; C106791:telithromycin